Hereditary Angioedema Therapeutic Market

Jan 2021| MRS026A| Market Research Studies

Report Highlights

The scope of this report is broad and covers different drug class of hereditary angioedema therapeutic, along with the treatment types for hereditary angioedema therapeutic and hereditary angioedema therapeutic. The market is broken down by drug class of hereditary angioedema therapeutic, treatment types and regional markets. Revenue forecasts from 2019 to 2025 are given for each major drug class of hereditary angioedema therapeutic, treatment type and regional market, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional hereditary angioedema therapeutic markets; it explains the major market drivers of the global hereditary angioedema therapeutic industry, current trends within the industry, major Treatment Types and the regional dynamics of the global hereditary angioedema therapeutic market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global hereditary angioedema therapeutic industry.

Report Includes

  • 62 tables
  • An up-to-date analysis of the global hereditary angioedema therapeutic market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for global Hereditary Angioedema Therapeutic market, and corresponding market share analysis by drug class, treatment Drug Class, route of administration and region for each market segment.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for hereditary angioedema therapeutic, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of new products and products still in the development and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the hereditary angioedema therapeutic market as compared to overall global economy.
  • Insight into the growth development strategies of major hereditary angioedema Therapeutic manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including CSL Limited, Attune, Ionis Pharmaceuticals, Inc., Shire Plc (Takeda), BioCryst Pharmaceuticals, Inc., Pharming Group N.V., Pharmaceuticals, Inc. and Adverum Biotechnologies, Inc.

Summary

Hereditary angioedema is an autosomal disorder, where the functional C1 esterase inhibitor protein level is less. This results in an increased concentration of bradykinin, which leads to fluid leakage from the blood vessels, along with swelling. Filtered concentrate of C1 esterase inhibitor is infused to HAE - affected patients for the prophylactic and acute attack treatment of HAE. Various drugs have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

As per the drug class, the different drug classes include C1-esterase inhibitor, Kallikrein inhibitor, B2 bradykinin receptor antagonist, and other drugs. Among which the C1-esterase inhibitor registered the major share in the market.

The global hereditary angioedema therapeutics market will grow from 3.3 billion in 2020 to 3.5 billion by 2025 at a five-year CAGR of 14.6%. The market for hereditary angioedema therapeutics is expected to grow, mainly due to the prevalence of rare diseases across the globe is rising and most of them are genetic disorders.

There has been a drastic growth in the investment and funding in the research and development activities towards hereditary angioedema therapeutic from the biopharmaceutical companies, which fuels the market expansion. However, the misdiagnosis of hereditary angioedema disease can restrict the market growth.

New product launches by key players, favorable reimbursement scenario, well-established healthcare infrastructure, and increased prevalence of hereditary angioedema, comparatively better reported ratio for diseases are the key reasons for the market growth in the North America region which holds a major share.

  • Table 1 : Research Programs/Design for This Report
  • Table 2 : Key Data Information from Secondary Sources
  • Table 3 : Key Data Information from Primary Sources
  • Table 4 : Global Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 5 : Global Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 6 : North America Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 7 : North America Hered3itary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 8 : USA Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 9 : USA Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 10 : Canada Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 11 : Canada Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 12 : Mexico Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 13 : Mexico Hereditary Angioedema Therapeutic By Treatment Type 2021-2025 (USD Million)
  • Table 14 : Europe Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 15 : Europe Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 16 : Germany Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 17 : Germany Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 18 : France Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 19 : France Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 20 : UK Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 21 : UK Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 22 : Italy Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 23 : Italy Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 24 : Rest of Europe Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 25 : Rest of Europe Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 26 : China Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 27 : China Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 28 : Japan Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 29 : Japan Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 30 : India Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 31 : India Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 32 : Korea Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 33 : Korea Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 34 : South East Asia Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 35 : South East Asia Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 36 : Brazil Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 37 : Brazil Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 38 : Argentina Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 39 : Argentina Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 40 : Egypt Hereditary Angioedema Therapeutic Market By Drug Class 2021-2025 (USD Million)
  • Table 41 : Egypt Hereditary Angioedema Therapeutic Market By Treatment Type 2021-2025 (USD Million)
  • Table 42 : Nigeria Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 43 : Nigeria Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 44 : Saudi Arabia Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 45 : Saudi Arabia Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 46 : South Africa Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Table 47 : South Africa Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Table 48 : Takeda Pharmaceutical Company Limited Company Details
  • Table 49 : Takeda Pharmaceutical Company Limited Description and Business Overview
  • Table 50 : Takeda Pharmaceutical Company Limited Financial Analysis
  • Table 51 : Takeda Pharmaceutical Company Limited Product Portfolio
  • Table 52 : Takeda Pharmaceutical Company Limited Recent Development
  • Table 53 : Sanofi Company Details
  • Table 54 : Sanofi Description and Business Overview
  • Table 55 : Sanofi Financial Analysis
  • Table 56 : Sanofi Product Portfolio
  • Table 57 : Sanofi Recent Development
  • Table 58 : BioCryst Pharmaceuticals, Inc. Company Details
  • Table 59 : BioCryst Pharmaceuticals, Inc. Description and Business Overview
  • Table 60 : BioCryst Pharmaceuticals, Inc. Financial Analysis
  • Table 61 : BioCryst Pharmaceuticals, Inc. Ltd Product
  • Table 62 : BioCryst Pharmaceuticals, Inc. Recent Development
  • Figure 1 : MRS Methodology for Estimating the Market Demand and Forecast
  • Figure 2 : Bottom-Up and Top-Down Approaches for This Report
  • Figure 3 : Data Triangulation
  • Figure 4 : Global Hereditary Angioedema Therapeutic Market by Drug Class 2021-2025 (USD Million)
  • Figure 5 : Global Hereditary Angioedema Therapeutic Market by Growth and Revenue 2021-2025 (USD Million)
  • Figure 6 : Global Hereditary Angioedema Therapeutic Market by Treatment Type 2021-2025 (USD Million)
  • Figure 7 : Global Hereditary Angioedema Therapeutic Market by Country 2021-2025 (USD Million)
  • Figure 8 : Porter's Five Forces Analysis
  • Figure 9 : Channels of Distribution
  • Figure 10 : Company Profiles
  • Figure 11 : Hereditary Angioedema Therapeutic Value Chain Analysis
  • Figure 12 : Global Hereditary Angioedema Therapeutic Market Share, By Drug Class, 2021
  • Figure 13 : Global Hereditary Angioedema Therapeutic Market Share, By Treatment Type, 2021
  • Figure 14 : Global Hereditary Angioedema Therapeutic Market Share, By Region, 2021
  • Figure 15 : Hereditary Angioedema Therapeutic Market Overview (Drivers, Restraints, Opportunities)

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report